DKSH (DKSH) H2 2023 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2023 earnings summary
31 Oct, 2026Executive summary
FY 2023 net sales rose 5.3% at CER, Core EBIT grew 12.6% at CER, and Core EBIT margin expanded 15 bps to 3.0%.
Free cash flow reached CHF 282.3 million, with cash conversion of 137.0%; the proposed ordinary dividend increased 4.7% to CHF 2.25 per share.
Financial highlights
Net sales were CHF 11,066.0 million versus CHF 11,320.2 million in FY 2022; CER growth was 5.3%.
Core EBIT was CHF 329.9 million versus CHF 319.2 million; CER growth was 12.6%, including single-digit organic growth and margin-accretive M&A.
Core profit after tax was CHF 206.0 million versus CHF 208.4 million; CER growth was 5.8%.
Free cash flow rose to CHF 282.3 million from CHF 209.5 million; cash conversion improved to 137.0% from 100.5%.
Outlook and guidance
FY 2024 commitment: sales growth above weighted GDP at CER in fast-growing Asian markets and Core EBIT growth at CER.
FY 2024 indications: M&A contribution to net sales of 0.5%–1.5%, FX impact of (3%)–(5%) if current spot rates prevail, tax rate of 27%–29%, and capex of 0.5% of net sales.
Outlook assumes Asia Pacific economic growth and stable exchange rates, and is subject to unforeseen events.
Latest events from DKSH
- NewBridge extends healthcare into MENA and is expected to be accretive from closing.DKSH
M&A announcement - EPS up 18.2%, Core EBIT up 3.6%, and strong cash flow highlight robust H1 2026.DKSH
H1 2026 - Core EBIT up 6.7% to CHF 349m, margin expands, and dividend rises 6.4% amid strong cash flow.DKSH
H2 2025 - Net sales and core EBIT rose, margins expanded, and M&A activity remained strong in H1 2025.DKSH
H1 2025 - Accelerated growth, margin expansion, and impactful M&A drive a robust midterm outlook.DKSH
CMD 2024 - Core EBIT up 8.2% at CER, net sales up 3.3% at CER, strong cash flow and margin expansion.DKSH
H1 2024 - Core EBIT up 8.4% at CER, margin expands to 3.1%, and 2025 outlook remains positive.DKSH
H2 2024